BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 26494234)

  • 21. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.
    Liu Y; Malin JL; Diamant AL; Thind A; Maly RC
    Breast Cancer Res Treat; 2013 Feb; 137(3):829-36. PubMed ID: 23263740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis.
    Bell RJ; Fradkin P; Schwarz M; Davis SR
    Menopause; 2013 Jan; 20(1):15-21. PubMed ID: 22948136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.
    Payne H; Mason M
    Br J Cancer; 2011 Nov; 105(11):1628-34. PubMed ID: 22009028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance and persistence of endocrine adjuvant breast cancer therapy.
    Güth U; Myrick ME; Kilic N; Eppenberger-Castori S; Schmid SM
    Breast Cancer Res Treat; 2012 Jan; 131(2):491-9. PubMed ID: 21976056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time.
    Cluze C; Rey D; Huiart L; BenDiane MK; Bouhnik AD; Berenger C; Carrieri MP; Giorgi R
    Ann Oncol; 2012 Apr; 23(4):882-90. PubMed ID: 21788360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Widmark A; Klepp O; Solberg A; Damber JE; Angelsen A; Fransson P; Lund JA; Tasdemir I; Hoyer M; Wiklund F; Fosså SD; ;
    Lancet; 2009 Jan; 373(9660):301-8. PubMed ID: 19091394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Criteria for evidence-based patient information].
    Steckelberg A; Berger B; Köpke S; Heesen C; Mühlhauser I
    Z Arztl Fortbild Qualitatssich; 2005; 99(6):343-51. PubMed ID: 16121649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current decision-making in prostate cancer therapy.
    Cox J; Amling CL
    Curr Opin Urol; 2008 May; 18(3):275-8. PubMed ID: 18382237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient and disease factors affecting the choice and adherence to active surveillance.
    Dall'Era MA
    Curr Opin Urol; 2015 May; 25(3):272-6. PubMed ID: 25692724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer elder alert. Living with treatment choices and outcomes.
    Pickett M; Bruner DW; Joseph A; Burggraf V
    J Gerontol Nurs; 2000 Feb; 26(2):22-34; quiz 54-5. PubMed ID: 10776173
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer patients' report on communication about endocrine therapy and its association with adherence.
    Jung B; Stoll C; Feick G; Prott FJ; Zell J; Rudolph I; Huebner J
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):465-70. PubMed ID: 26494234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Communication preferences of patients with prostate cancer : Preferences regarding the communication of bad news of patients with prostate cancer in Germany-results of an anonymous patient survey].
    Merseburger AS; Kramer MW; Scheithe K; Colling C
    Urologe A; 2016 Oct; 55(10):1339-1346. PubMed ID: 27306355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Information-oriented patients and physician career satisfaction: is there a link?
    Fang H; Rizzo JA
    Health Econ Policy Law; 2011 Jul; 6(3):295-311. PubMed ID: 20701828
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.